OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
6796$60.9056

Medimaging Integrated Solution Inc

Medical Equipment, Supplies & DistributionVerified

The company's capital structure is characterized by a debt-to-equity ratio of 0.57, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 4.04, suggesting the company has sufficient short-term assets to cover its liabilities. However, the company's free cash flow is negative at -43,174,000 TWD, which may indicate challenges in generating sufficient cash from operations to fund its capital expenditures. Profitability metrics show that the company is currently unprofitable, with a net loss of 10,230,000 TWD and a return on equity of -1.31%. These figures are below the industry median for profitability, as the company is not generating positive returns for its shareholders. The operating loss of 19,822,000 TWD further highlights the company's operational inefficiencies. The company's revenue is not segmented by geographic regions or product lines in the available data, making it difficult to assess the concentration of its revenue sources. However, the lack of detailed segment reporting may suggest a relatively concentrated business model, which could expose the company to higher risks if demand in a particular region or product line declines. The company's growth trajectory is uncertain, as the available data does not provide specific outlook figures for the current or next fiscal year. The negative operating and net income figures suggest that the company may need to implement cost-cutting measures or increase sales to improve its financial performance. The company's capital expenditures of -46,302,000 TWD indicate ongoing investment in its operations, which could be a sign of expansion or modernization efforts. The risk assessment indicates that the company faces liquidity risks, as its net cash is negative after subtracting total debt. The dilution risk is assessed as low, suggesting that the company is not currently issuing a significant number of new shares that could dilute existing shareholders' equity. The company's financial performance and liquidity position may be further impacted by its ability to manage its debt and improve its cash flow generation. Recent events and filings have not been provided in the available data, so it is not possible to assess the company's recent performance or strategic initiatives. The company's financial health and future prospects will depend on its ability to address its current financial challenges and improve its operational efficiency.

30-day price · 6796-8.50 (-11.9%)
Low$60.10High$79.50Close$62.90As of21 May, 00:00 UTC
Profile
CompanyMedimaging Integrated Solution Inc
Ticker6796.TW
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. Medimaging Integrated Solution Inc is a medical equipment and supplies company that generates revenue primarily through the sale and distribution of medical imaging systems and related products.

Classification. The company is classified under the Healthcare Services & Equipment business sector and the Medical Equipment, Supplies & Distribution industry with a confidence level of 0.92.

The company's capital structure is characterized by a debt-to-equity ratio of 0.57, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 4.04, suggesting the company has sufficient short-term assets to cover its liabilities. However, the company's free cash flow is negative at -43,174,000 TWD, which may indicate challenges in generating sufficient cash from operations to fund its capital expenditures. Profitability metrics show that the company is currently unprofitable, with a net loss of 10,230,000 TWD and a return on equity of -1.31%. These figures are below the industry median for profitability, as the company is not generating positive returns for its shareholders. The operating loss of 19,822,000 TWD further highlights the company's operational inefficiencies. The company's revenue is not segmented by geographic regions or product lines in the available data, making it difficult to assess the concentration of its revenue sources. However, the lack of detailed segment reporting may suggest a relatively concentrated business model, which could expose the company to higher risks if demand in a particular region or product line declines. The company's growth trajectory is uncertain, as the available data does not provide specific outlook figures for the current or next fiscal year. The negative operating and net income figures suggest that the company may need to implement cost-cutting measures or increase sales to improve its financial performance. The company's capital expenditures of -46,302,000 TWD indicate ongoing investment in its operations, which could be a sign of expansion or modernization efforts. The risk assessment indicates that the company faces liquidity risks, as its net cash is negative after subtracting total debt. The dilution risk is assessed as low, suggesting that the company is not currently issuing a significant number of new shares that could dilute existing shareholders' equity. The company's financial performance and liquidity position may be further impacted by its ability to manage its debt and improve its cash flow generation. Recent events and filings have not been provided in the available data, so it is not possible to assess the company's recent performance or strategic initiatives. The company's financial health and future prospects will depend on its ability to address its current financial challenges and improve its operational efficiency.
Key takeaways
  • The company is currently unprofitable with a net loss of 10,230,000 TWD and a negative return on equity of -1.31%.
  • The company's liquidity position is medium, with a current ratio of 4.04, but it has a negative free cash flow of -43,174,000 TWD.
  • The company's debt-to-equity ratio is 0.57, indicating a moderate level of debt financing.
  • The company's capital expenditures of -46,302,000 TWD suggest ongoing investment in its operations.
  • The company's risk assessment indicates medium liquidity risk and low dilution risk.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyTWD
Revenue$97.1M
Gross profit$40.9M
Operating income-$19.8M
Net income-$10.2M
R&D
SG&A
D&A
SBC
Operating cash flow$27.9M
CapEx-$46.3M
Free cash flow-$43.2M
Total assets$1.39B
Total liabilities$603.5M
Total equity$782.8M
Cash & equivalents$114.6M
Long-term debt$445.1M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$485.9M$86.6M$66.5M$96.7M
FY-3$502.1M$59.6M$70.0M$48.3M
FY-2$537.1M$91.9M$74.1M-$153.5M
FY-1$538.9M-$3.8M$5.6M-$126.0M
FY0$661.4M$17.9M$7.7M$9.8M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$715.8M$486.1M$224.3M
FY-3$841.4M$648.1M$275.1M
FY-2$1.34B$792.5M$237.4M
FY-1$1.36B$742.5M$114.6M
FY0$1.57B$745.4M$192.2M
PeriodOCFCapExFCFSBC
FY-4$46.0M-$30.8M$96.7M
FY-3$112.3M-$51.8M$48.3M
FY-2$168.4M-$199.3M-$153.5M
FY-1-$50.4M-$124.1M-$126.0M
FY0-$16.2M-$37.1M$9.8M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$97.1M-$19.8M-$10.2M-$43.2M
FQ-6$122.5M$2.3M$2.4M-$34.5M
FQ-5$104.1M-$20.7M-$22.7M-$32.4M
FQ-4$215.2M$34.5M$36.1M$46.2M
FQ-3$133.7M$1.3M$1.4M$7.4M
FQ-2$154.6M-$5.0M-$29.6M-$25.6M
FQ-1$152.8M-$9.6M$2.2M$5.2M
FQ0$220.3M$31.3M$33.8M$40.2M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$1.39B$782.8M$114.6M
FQ-6$1.36B$726.7M$129.2M
FQ-5$1.31B$706.4M$114.6M
FQ-4$1.36B$742.5M$114.6M
FQ-3$1.33B$744.3M$214.2M
FQ-2$1.31B$695.5M$195.5M
FQ-1$1.35B$698.2M$183.7M
FQ0$1.57B$745.4M$192.2M
PeriodOCFCapExFCFSBC
FQ-7$27.9M-$46.3M-$43.2M
FQ-6$2.6M-$97.1M-$34.5M
FQ-5-$39.1M-$120.5M-$32.4M
FQ-4-$50.4M-$124.1M$46.2M
FQ-3$67.2M-$7.7M$7.4M
FQ-2-$8.8M-$17.6M-$25.6M
FQ-1-$16.8M-$28.8M$5.2M
FQ0-$16.2M-$37.1M$40.2M
Valuation
Market price$60.90
Market cap$2.33B
Enterprise value$2.66B
P/E
Reported non-GAAP P/E
EV/Revenue27.4
EV/Op income
EV/OCF95.4
P/B3.0
P/Tangible book3.0
Tangible book$782.8M
Net cash-$330.5M
Current ratio4.0
Debt/Equity0.6
ROA-0.7%
ROE-1.3%
Cash conversion-2.7%
CapEx/Revenue-47.7%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 369 companies
Metric6796Activity
Op margin-20.4%3.9% medp25 -31.3% · p75 14.4%below median
Net margin-10.5%2.4% medp25 -30.5% · p75 11.1%below median
Gross margin42.2%46.7% medp25 28.2% · p75 63.1%below median
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-47.7%-4.8% medp25 -11.6% · p75 -2.4%bottom quartile
Debt / equity57.0%17.9% medp25 2.7% · p75 52.2%top quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 09:55 UTC#b33ca96e
Market quoteclose TWD 69.70 · shares 0.04B diluted
no public URL
2026-05-10 09:55 UTC#ca0ecdb6
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 02:14 UTCJob: 63fb01d5